More recently, the 2021 WHO classification places a greater emphasis on molecular characteristics to enhance the diagnostic accuracy of GBM, including IDH wild-type status, Epidermal Growth Factor Receptor (EGFR) amplification and Telomerase Reverse Transcriptase (TERT) promotor mutations [3]. This evidence concerns the gene EGFR and glioblastoma.